All In Biotech

Drug Trial Radar · NCT04099966

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Apr 1, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Mitchell CairoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 day, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

Conditions

  • Acute Leukemia
  • Severe Aplastic Anemia
  • Non-hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Kostmann
  • Diamond Blackfan Anemia
  • Amegakaryocytic Thrombocytopenia
  • Sickle Cell Disease
  • Beta-Thalassemia

Interventions

  • alpha beta depletionDrug

    donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. incidence of adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cellsTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New York Medical College

    Valhalla, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.